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Introduction
Cationic lipid/DNA complexes (lipoplexes) have been successfully employed for in vitro and in vivo gene delivery, and they are being evaluated in an increasing number of human gene therapy clinical trials. [1] [2] [3] [4] [5] [6] However, the lack of control over the biophysical and molecular parameters influencing lipoplex formation represents a limitation to consistently obtaining well-defined, stable and monodisperse formulations with reproducible biological activity.
When cationic liposomes and DNA are mixed, they interact electrostatically, reorganize and form lipoplexes wherein the DNA has been shown to induce aggregation and fusion of cationic liposomes. [7] [8] [9] [10] Many lipoplex preparations are physically unstable and their transfection activity can decrease with time. Such problems can be avoided for in vitro experiments by using low concentrations of DNA and lipids, but clinical testing requires much higher quantities of DNA. Consequently, for in vivo applications the lipoplexes are usually prepared fresh and used shortly after the DNA and cationic liposomes are mixed. 1, 2, 11, 12 Most of the clinical formulations have to be prepared freshly by the physician at the bedside prior to injecting them into patients. Thus, production of stable lipoplex formulations in a single vial, which do not have to be prepared immediately before use represents a desirable practical goal.
Recent publications have demonstrated increasing attention to the problems of developing and characterizing physically stable lipoplex formulations. Quantitative analytical assays to characterize the physical properties of lipoplexes have just been reported. 10, 13 Other laboratories have focused on the development of stable lipoplex formulations and demonstrated that the addition of compounds such as spermidine, polyethyleneglycol 14 or surfactants 15, 16 can enhance the stability and prevent the aggregation of lipoplexes. Although very promising, these approaches used relatively low DNA concentrations (200 g/ml and below) and the added excipients may complicate the characterization, toxicity and manufacturing of these formulations. Moreover, a more detailed understanding of the real benefits of these additives needs further investigation.
Here, we report a systematic survey to identify and characterize monodisperse stable lipoplex formulations based on quantitative biological and analytical physicalchemical assays. The results show that by combining two very simple procedures, liposome extrusion and controlled mixing, aggregation problems can be avoided. In this way, well-defined (monodisperse) and stable lipoplexes with high transfection activities can be prepared reproducibly without the addition of any other components. An isotonic vehicle that can be used to prepare stable frozen single vial formulations without affecting physical properties or biological activity is also described.
Results

Parameters influencing the efficacy of lipoplexes
Cationic lipid/DNA ratio effects on in vitro transfection activity: In order to optimize the transfection efficiency of the lipoplexes, several laboratories have examined the parameters that affect the level of transfection. 1, 2, [17] [18] [19] From these studies, it appears that DNA and lipid concentration, cationic lipid/DNA molar ratio, the presence or absence of helper lipids (ie DOPE or cholesterol) and the type of vehicle (ionic strength) used to make the lipoplexes, are among the critical parameters. With DMRIE, one of the cationic lipids currently used in clinical trials, the optimum molar ratio (number of mole of cationic lipids per mole of DNA phosphate) for in vitro transfection efficiency is between 0.25 and 1.5 17, 20 (data not shown). As the cationic lipid/DNA molar ratio increased above a value of 2, the activity of DMRIE progressively declined, and with a large excess of lipids, toxicity became a limiting factor.
Cationic lipid/DNA ratio effects on physical stability: The results in Figure 1a illustrate the problem of lipoplex physical stability at charge ratio near 1, wherein the net charge on the lipoplex approaches 0. Freshly mixed lipoplexes prepared by the classical method had a mean diameter of 200-500 nm whereas after 6 h of incubation at room temperature the formulations prepared near the charge neutral condition aggregated to a particle diameter of 2000-2500 nm ( Figure 1a ). As the time course was prolonged, the particles continued to increase in size (data not shown). These problems were greater when higher DNA concentrations were used. Under these conditions, severe aggregation resulted in low transfection activity 2 (data not shown). Since 0.25 and 0.5 DMRIE:DOPE/DNA molar ratios gave high in vitro transfection activity 17, 20 with a relatively low tendency to aggregate, we have focused our efforts on the characterization of formulations prepared at these two ratios.
Order of addition: Another parameter influencing the particle size of lipoplexes is the order of addition of DNA and lipids. Lack of attention to this preparation variable can lead to extensive aggregation. In order to produce the smallest complexes at low cationic lipid/DNA charge ratios (Ͻ1), DMRIE:DOPE and DNA need to be mixed by adding the liposomes into the excess DNA (Figure 1b ). Large aggregates were produced when the DNA was added into the lipid. When the complexes were prepared at a high cationic lipid/DNA charge ratio (Ͼ1), the optimal order of addition was reversed, and smaller complexes were produced when the DNA was added into the excess cationic liposomes (Figure 1c) . All vehicles and all cationic lipids tested obeyed these general rules (data not shown). As mentioned previously, large aggregation resulted in lower transfection activity 2 (data not shown). The methods for reproducible preparation of physically stable and homogenous lipoplex formulations described in this report were developed in recognition of these fundamental properties of lipoplex preparation. The continuous flow mixing method described here avoids order of addition concerns by bringing the cationic liposomes and DNA together at a constant ratio during the entire mixing procedure. The mixing method also allows the rate of mixing to be precisely controlled.
Preparation of cationic liposomes with discrete sizes
Hand shaken or vortexed liposomes (large multilamellar vesicles, MLV) are heterogeneous and one would therefore predict that lipoplexes formed from these cationic MLV liposomes might also be heterogeneous. The physical properties and transfection activities of lipoplexes prepared from heterogeneous MLV were, therefore, compared with lipoplexes prepared from homogeneous extruded liposomes with well-defined sizes. However, in order to accomplish this it was first necessary to demonstrate that it was possible to prepare cationic liposomes with well-defined sizes.
The results in Figure 2 compare the particle size distributions of MLV DMRIE:DOPE liposomes with liposomes that were extruded through either 400 or 100 nm membranes. The extruded liposomes were much more homogeneous than the MLV and their diameter corresponded closely to the pore diameter of the filter. Liposome preparations utilizing four different cationic lipids exhibited similar behavior, and the same results were obtained with the three different vehicles, water, saline and sorbitol/sodium acetate buffer (S/A: 5% sorbitol/20 mm sodium acetate pH 6 buffer) (data not shown). The production of these liposomes was reproducible and no significant variability was observed between different investigators.
A controlled mixing method to produce monodisperse lipoplex formulations Since the order of addition of DNA and cationic liposomes was shown to be critical for controling the size of the lipoplexes, we developed a method to mix both components simultaneously, at a fixed ratio and at a controlled speed. This novel method was designed to be simple, scaleable and to minimize handling inconsistencies among different investigators.
Cationic liposomes and DNA were mixed together with the aid of a syringe pump in order to control the rate of mixing and obviate the need to control the order of addition (Figure 3 ). DNA solution and cationic liposomes were loaded separately into tuberculin syringes connected to an i.v. extension set. Then, the syringes were placed on the pump, and the plunger was adjusted on the syringes to put the fluid level at the same position for both DNA and liposome preparations. The mixing took place in the T-connector when the plunger of the syringes was pushed simultaneously and at the same speed ( Figure 3) .
The data in Figure 4 show the particle size distributions of the DMRIE:DOPE/DNA complexes prepared with 400 nm extruded liposomes at 0.25 molar ratio and at various mixing rates. For the 400 nm extruded liposomes, the optimal mixing rate was determined to be between 3.24 and 8.1 ml/min (Figure 4a) . At higher mixing rates aggregation was observed (Figure 4b and c) . For the 100 nm extruded liposomes, the 15.7 ml/min rate was found to be optimal for producing the smallest particle size distribution; at low (3.24 ml/min) and at high rates (Ͼ22.8 ml/min) aggregation occurred (data not shown). Thus, the optimal mixing rate varied according to the starting liposome size. This semi-automated method, described for the first time, is a convenient way to mix cationic liposomes with DNA in a reproducible manner that eliminates the order of addition problem described earlier (Figure 1b and c) . The mixing rate had no significant effect on the particle size distribution of the lipoplexes formed from MLV liposomes (data not shown). Thus, for all lipoplex formulations prepared by the controlled mixing method, the mixing rate used was 15.7 ml/min for the 100 nm extruded and unextruded liposomes and 8.1 ml/min for the 400 nm extruded liposomes.
The particle size distributions of the lipoplexes produced from extruded liposomes and by the controlled mixing method were more homogeneous than those obtained from MLV (Figures 5a and 6 ). As the liposomes decreased in size from MLV to 400 and 100 nm extruded vesicles, the particle size distribution of the resulting lipoplexes decreased as seen by the higher percentage of lipoplexes in the small size range (Ͻ 200 nm). Indeed, with extruded liposomes, no lipoplexes were у1000 nm whereas with the MLV a large percentage of the lipoplexes exceed 1000 nm. In the same way, a small lipoplex population (Ͻ200 nm) was observed only with the extruded liposomes. Moreover, the visual appearances of the formulations differed considerably. When MLV liposomes were used as a starting material, large particles were always visible. Formulations prepared from 100 nm extruded liposomes were always clearer than formulations prepared with 400 nm extruded liposomes. It is important to appreciate that the dynamic laser light scattering instrumentation used here is not designed to accurately measure particles greater than about 1000 or 2000 nm in diameter. Therefore, aggregated samples containing visible particles are difficult to characterize by laser light scattering because many of the particles in the samples may be too large to be determined accurately by the instrument. However, the presence of these large aggregates could be quantified with the filtration assay (see Figure 7) .
The production of homogeneous and monodisperse lipoplexes was DNA concentration dependent. By reducing the quantity of DNA by 10-or 100-fold, a smaller lipoplex particle size distribution was obtained ( Figure 5b ). Low concentrations of DNA (0.1-0.5 mm) are acceptable for most in vitro transfection experiments, but for in vivo studies and for clinical use, higher concentrations (1-4 mm) are often necessary. A method for producing very small lipoplexes might involve producing them under low concentrations and then concentrating the final product. This approach to producing small particle size lipoplexes at a high DNA concentrations is currently being tested.
In addition, in order to be simple and scaleable, this novel method was designed to reduce handling inconsistencies among different investigators. Thus, two different investigators produced formulations of DMRIE:DOPE/ DNA prepared at 0.25 molar ratio in saline. As show in Figure 6 , the production of lipoplexes with extruded liposomes and the controlled mixing method was reproducible and no significant variability was observed between different investigators (Figure 6b and c) . In contrast, when MLV liposomes were used the lipoplex formulations differed significantly among preparations and between investigators (Figure 6a) .
The methods for reproducible preparation of physically stable and homogenous lipoplex formulations described in this report were developed in recognition of these fundamental properties of lipoplex preparation. The continuous flow mixing method described here avoids order of addition concerns by bringing the cationic liposomes and DNA together at a constant ratio during the entire mixing procedure. The mixing method also allows the rate of mixing to be precisely controlled.
Physical characterization of lipoplexes
The stability of the lipoplexes formed from MLV or extruded liposome and by the controlled mixing method, was monitored by using analytical methods previously described. 13 The filtration assay, which measures the percentage of lipid and DNA recovered after filtration of lipoplexes through different pore size filters, was shown to be a sensitive way to quantitatively assess changes in particle size and heterogeneity, and provided information on the extent of aggregation of the formulations. When samples contained large particles, the aggregated product was retained on the filter and a corresponding reductions in DNA and lipid recoveries were determined. These assays also provided information about whether the formulations could be easily handled without loss of material due to adsorption. Without an analytical assay, this adsorption problem could easily have gone unnoticed and could have a negative impact on reproducibility.
Unextruded or extruded liposomes were mixed with DNA at 0.5 molar ratio and at the appropriate mixing rate. The resulting lipoplexes were filtered through 1000 nm (data not shown), 600 nm or 400 nm membranes (Figure 7b and c) , and the lipid and DNA recoveries before and after filtration were determined. Without filtration, all the formulations exhibited comparable lipid ( Figure 7a ) and DNA recoveries (data not shown) approaching 100% of theoretical. The 600 nm filtration of lipoplexes prepared from MLV removed 40-80% of the lipid depending on the vehicle (Figure 7b) . The S/A vehicle (5% sorbitol/20 mm sodium acetate pH 6 buffer) gave the highest recovery and saline gave the lowest. The product recovery after filtration from lipoplexes prepared with the extruded liposomes was greater than from lipoplexes prepared with MLVs. This indicated that lipoplexes prepared from extruded liposomes contained less aggregated material than those produced from unextruded liposomes. For MLVs prepared in saline, less than 20% of lipid was recovered after 600 nm filtration whereas for the extruded liposomes 75% was recovered (Figure 7b ).
The amount of lipid recovered after filtration was also affected by the composition of the suspending vehicle. The lipid recoveries after filtration were greater when the lipoplexes were formulated in S/A buffer than when prepared in either water or saline (Figure 7b and c) . This result suggested that the lipoplex formulations prepared in S/A were more uniform and contained fewer large particles. The differences in homogeneity between MLV and extruded liposomes prepared in S/A, were apparent after filtration through 600 nm membranes. Indeed, Ͼ95% of lipid was recovered with extruded liposomes, whereas MLV exhibited less than 65% recovery (Figure 7b ). These differences were brought out more dramatically when the lipoplexes were filtered through a 400 nm membrane (Figure 7c ). Similar conclusions were made for formulations prepared at 0.1 and 0.25 DMRIE:DOPE/DNA molar ratios (data not shown). The percentage of DNA recovered was also monitored and the results obtained were qualitatively similar (data not shown). However, since approximately 50% of the DNA is free in these formulations, 13 the differences for DNA recovery between the formulations were less pronounced than those with the lipid assay. Under all conditions examined, the formulations prepared by the controlled mixing method and with extruded liposomes, showed higher recoveries (lipids and DNA) than lipoplexes prepared from unextruded liposomes. The filtration assay in combination with dynamic light scattering demonstrated the advantages of using extruded liposomes and controlled mixing to produce monodisperse lipoplexes. We then investigated which components of the S/A buffer were responsible for producing these uniform and smaller particles by monitoring lipid recoveries after filtration through 400 nm membranes (Figure 7c ). When lipids and DNA were mixed in water or sorbitol vehicles, the resulting lipoplexes could not pass through the 400 nm filters and all the lipids were lost. Sodium acetate was sufficient to produce a formulation that could be filtered through a small pore membrane. The results with 20 mm sodium acetate alone were comparable to those seen in the complete S/A vehicle (Figure 7c ). In summary, these assays have demonstrated that lipoplexes produced from extruded liposomes under controlled mixing conditions were markedly more stable and less aggregated than those produce from MLV liposomes.
In vitro transfection efficiency of new lipoplexes
The production of stable and monodisperse lipoplex formulations is beneficial only if the biological activity can also be retained. In this context, we tested the in vitro transfection efficiency of lipoplexes formed from unextruded or extruded liposomes using the controlled mixing method. The formulations were prepared in three different vehicles (water, saline, S/A) and at 0.25 and 0.5 DMRIE:DOPE/DNA molar ratios. The preparations made with 400 nm extruded liposomes were as active as MLV at the 0.5 molar ratio but less active than MLV when formulated at the 0.25 molar ratio (Figure 8 ). The formulations prepared with 100 nm extruded liposomes were the least active. Thus, lipoplexes prepared with larger liposomes were more active than those prepared from smaller liposomes. It is difficult, however, to conclude from these in vitro experiments which lipoplexes will be the most active in vivo, and these studies are underway. The relatively low activity of the smaller lipoplexes produced from 100 nm extruded liposomes could be due to a sedimentation problem as suggested, 18 since the larger DMRIE:DOPE/DNA complexes may facilitate cell surface contact by sedimentation.
The transfection efficiency of these new formulations was also tested on different cell types (data not shown). The relative transfection activity rankings among the different formulations were the same in three other cell lines (L293, UM449 and B16F10). In all of these cell lines, lipoplexes formed from 100 nm extruded liposomes were less active than lipoplexes prepared from 400 nm extruded liposomes or MLV (data not shown).
Production of frozen single vial formulations: stability and efficacy
The possibility of producing a physically stable, isotonic, single vial DMRIE:DOPE/DNA formulation was investigated. First, all formulations prepared by the controlled mixing method and tested previously ( Figure 8 ) were frozen quickly in ethanol/dry ice and then stored at −70°C. The results in Figure 9 show the in vitro transfec-
Figure 8 In vitro transfection activity of DMRIE:DOPE/DNA lipoplexes freshly prepared. Preparation of lipoplexes from unextruded or extruded (400 or 100 nm) liposomes, at various positive/negative molar ratios, in three different vehicles and transfection protocol were carried out as described in Materials and methods. The data show the percentage of ␤-galactosidase expression in Renca cells as a function of the molar ratio and liposome used as the starting material. (a) Water; (b) saline; (c) S/A. Data are the mean ± standard error of two separate experiments.
tion activities of lipoplexes before (Figure 9a ) and after freeze/thaw (Figure 9b ). The data indicated that all lipoplex formulations prepared in S/A buffer could be frozen and thawed without losing significant in vitro transfection activity. In contrast, the same formulations prepared in either water or isotonic saline lost in vitro transfection activity after being frozen and thawed. All lipoplexes formulated without sorbitol (MLV or extruded) lost more than 50% of their transfection activity (data not shown). The 20 mm sodium acetate was previously shown to be required for optimal physical stability (Figure 8c ). Thus, both the low ionic strength sodium acetate buffer and sorbitol were required to produce a stable single vial formulation that could be stored frozen.
The physical stability of frozen and thawed lipoplex formulations was examined. Lipoplexes prepared at 0.5 DMRIE:DOPE/DNA molar ratio were frozen, stored at −70°C for 1 month, thawed and assayed for lipid and DNA recoveries before and after 600 nm filtration ( Figure 10 ). Slight losses in lipid recovery from the unfiltered saline formulations and from the MLV formulation
Figure 9 In vitro transfection activity of DMRIE:DOPE/DNA lipoplexes frozen and thawed in Renca cells. Preparation of lipoplexes from unextruded or extruded (400 or 100 nm) liposomes, at 0.5 molar ratio, in three different vehicles, and transfection protocol were carried out as described in Materials and methods. (a) Freshly prepared lipoplexes; (b) frozen and thawed lipoplexes. Data are the mean ± standard error of two separate experiments.
Figure 10 Percentage of lipid and DNA recovery after filtration through various pore sizes of frozen and thawed lipoplexes. DMRIE:DOPE/DNA complexes were prepared, from unextruded or extruded (400 and 100 nm) liposomes, at 0.5 molar ratio in various vehicles and under a controlled mixing rate, according to the procedure described in Materials and methods. After being thawed, lipoplexes were unfiltered (a and c) or filtered through a pore size filter of 600 nm (b and d). Then, percentage of lipid and DNA recovered after filtration was determined as a function of the liposomes starting material size and vehicle used. (a-b) Percentage of lipid recovered before or after filtration; (c-d) percentage of DNA recovered before or after filtration.
prepared in water were noted (Figure 10a ). In contrast, the saline and water formulations were almost completely depleted of lipids by the 600 nm filtration procedure (Figure 10b ). This result can be compared with the results in Figure 6b which showed much higher lipid recovery following 600 nm filtration of freshly prepared lipoplexes. However, the 600 nm filtration assays indicated that all of the S/A formulations were essentially unchanged after freezing and thawing (Figure 10b) . Indeed, similar results were obtained for lipid recovery from the freshly prepared lipoplexes in S/A buffer (Figure 7b) . DNA recoveries revealed similar trends in the abilities of the formulations to withstand freeze/thaw (Figure 10c and d) . Filtration of lipoplexes prepared using extruded liposomes showed Ͼ90% DNA recoveries after freeze/thaw in S/A buffer, but not in water and saline. These results indicated that formulations prepared in either saline or water aggregated after freeze/thaw and were, therefore, not suitable for use as frozen formulations. In contrast, the S/A buffer stabilized the formulations against freezing and thawing.
Dynamic laser light scattering measurements of the frozen and thawed lipoplexes complemented the filtration data. Lipoplexes prepared in S/A buffer also showed no significant differences between any of the freshly prepared and frozen/thawed S/A formulations (Figures 11c and 2) . In contrast, the water and saline formulations exhibited evidence of aggregation following freeze/thaw (Figure 11a and b) . As mentioned previously, largely aggregated samples are difficult to characterize by laser light scattering quantitatively. However, the presence of large aggregates has been identified with the filtration assay ( Figure 10 ). These results were also in agreement with the biological activity of the frozen and thawed lipoplexes (Figure 9 ). Taken together these results suggested that the large aggregates produced after freezing and thawing of the lipoplexes were not biologically active in the in vitro transfection assay.
A study was initiated to determine the feasibility of using the S/A vehicle for long-term storage of lipoplexes. In vitro transfection activity of a formulation prepared with MLV liposomes, frozen and thawed after 1 week, 1, 3 or 12 months, exhibited similar in vitro transfection activity compared with a freshly prepared lipoplex formulation ( Figure 12 ). Fast freezing in a dry ice/alcohol bath or −70°C freezer was preferred to a formulation that was frozen slowly at −20°C (data not shown), but once frozen, the samples could be stored at −20°C. The stability of the individual compounds (DNA and lipids) was analyzed after 1-year storage at −20°C. As reflected by the biological activity of these frozen and thawed formu- lations (Figure 12 ), the DNA was still intact as analyzed by agarose gel electrophoresis (data not shown). Analysis of the lipid components by thin layer chromatography revealed Ͼ90% integrity of both the DMRIE and the DOPE (data not shown). The utility of the S/A buffer for the long-term storage of the new lipoplex formulations is currently underway, as well as more detailed studies on DNA and lipid stability analyzed by HPLC, 21 TLC and NMR.
Discussion
These studies were intended to identify a simple and scaleable method to reproducibly prepare stable, monodisperse lipoplexes and to prepare a physically stable, single-vial, DMRIE:DOPE/DNA formulation that retained biological activity after freezing and thawing. The need to carefully optimize these methods was motivated by the observation that better transfection activity was obtained under conditions in which the complexes became increasingly less physically stable. Since heterogeneous and aggregated materials are difficult to control and can lead to irreproducible results, these physical stability issues are important from basic research, product development and clinical application perspectives.
In order to reproducibly prepare well characterized, homogeneous, and stable formulations with high transfection activity, a liposome extrusion method and a controlled mixing method were developed. These methods allowed DMRIE formulations to be prepared at higher DNA concentrations (у330 g/ml). The methods also bypassed fundamental technical problems associated with controlling the mixing rate and order of addition of the cationic liposomes and DNA during complex formation. The physical stability and in vitro transfection activities of DMRIE:DOPE/DNA formulations prepared in this way were compared. The use of MLV (prepared by vor-tex mixing) led to the production of large and heterogeneous complexes with high in vitro transfection activity but with poor physical stability (based on visual appearance, laser light scattering and lipid recovery after filtration). The use of extruded liposomes led to the production of more homogeneous, less aggregated complexes. The formulations prepared with 400 nm extruded liposomes were as active as vortexed liposomes and more active than those prepared with 100 nm extruded liposomes. However, formulations prepared from 100 nm extruded liposomes were very physically stable, had a low tendency to aggregate and produced a transparent solution that was easy to handle. Formulations prepared in S/A buffer were highly active in vitro and were more physically stable than formulations prepared in either water or saline. Recovery from the S/A vehicle was greater than from the saline or water vehicles indicating that the S/A formulations contained smaller and more uniform particles. This effect of S/A buffer on physical stability could be due to the controlled pH, the low ionic strength, the monovalent buffer species, the sugar species or a combination of these. Under all conditions examined, the formulations prepared with extruded liposomes showed better recoveries and were more homogeneous than formulations prepared with MLV.
From the biological data reported here it appeared that larger (400-800 nm) lipoplexes were more active in in vitro transfection experiments than the smaller ones (100-400 nm). This observation for DMRIE:DOPE has been previously reported, 17 and a recent study comparing the in vivo activity of lipoplexes produced from either MLV or SUV (small unilamellar vesicles) reached a similar conclusion. 22 However, for in vivo applications, the benefits of using small versus large lipoplexes, may depend on the route of administration, as well as on the intended cell or tissue targeted. Indeed, as reported by Liu et al 22 the advantage of using large lipoplexes for intravenous administration seems to be when the lung is the primary target. In other biological models (tumor, spleen, liver or hematopoietic cells), the relative benefits of larger and smaller lipoplexes need further investigation. It is also obvious from the freeze/thaw transfection experiments that very large lipoplexes produced after freeze/thaw in saline or water are not desirable since they lose most of their in vitro transfection activity. Nevertheless, it has been shown by Templeton et al 23 that the production of homogeneous lipoplex formulations by the extrusion method leads to improved systemic delivery.
A physically stable, single vial, frozen formulation was identified. The low ionic strength formulations (S/A buffer) which contained a neutral non-reducing sugar, retained the biological activity and physical characteristics of the lipoplexes after freeze/thaw. One S/A formulation was stable for more than 1 year at −20°C. In contrast, saline and water formulations were physically unstable to freeze/thaw. The importance of producing stable lipoplex formulations for gene delivery is becoming widely appreciated and several recent publications have claimed that stable lipoplexes can be produced by addition of 'helper' compounds such as spermidine, polyethyleneglycol 14 or surfactants. 15, 16 These papers described lipoplexes that were formed in the presence of excess positive charge and the lipoplexes were prepared at lower DNA concentrations (р200 g/ml) than those used in this study (from 330 g/ml to 1.3 mg/ml). Moreover, previous studies have not thoroughly analyzed the physical stability of the lipoplexes, and most of these studies have looked at relatively short-term storage (р3 months). All these studies have emphasized the use of additional compounds, which were claimed to be required to get stable formulations. [14] [15] [16] The addition of these extra components increases the complexity of the formulations and accordingly makes their characterization, and manufacturing more difficult to control. In contrast, our method demonstrates that DNA and lipids can be mixed together to form a stable single vial formulation without the addition of other components and with a very simple and scaleable two-step procedure.
The reproducible production of well-characterized lipoplex preparations is also critical for the understanding of the molecular, biophysical and biological mechanisms of lipoplex formation and action. Recent studies with oligonucleotides 24, 25 or plasmid DNA [26] [27] [28] have shown that the mechanism of cationic lipid-mediated nucleic acid delivery can be studied at the cellular level and that the molecular and cellular barriers can be characterized. The preparation of well-characterized, stable monodisperse lipoplexes will help to identify which structural features of lipoplexes are optimal for efficient DNA delivery and will aid in elucidating structure-function relationships. This will also permit a more rational approach to further improving the efficiency of these self-assembled delivery systems.
In summary, the results of these studies provide a platform for characterizing and comparing the behavior of synthetic gene delivery systems. In addition, a physically stable (over 1 year), isotonic, single vial DMRIE:DOPE/ DNA formulation was described. Formulations of this kind may provide more reproducible in vivo data and may also be useful as practical clinical products.
Materials and methods
Reagents
Cationic lipid 1,2-dimyristyloxypropyl-3-dimethyl-hydroxyethyl ammonium bromide (DMRIE) was synthesized as described. 17 Dioleoyl-phosphatidylethanolamine (DOPE) was purchased from Avanti Polar lipids (Alabaster, AL, USA). ␤-Galactosidase standard (grade VIII from E. coli) and NaCl were purchased from Sigma (St Louis, MO, USA). Chlorophenol red pyranogalactoside (CPRG) was obtained from Boehringer Mannheim (Indianapolis, IN, USA). All chemicals are reagent grade: Ultra pure agarose (Gibco BRL, Gaithersburg, MD, USA) Tris-HCl and EDTA (Fisher, Irvine, CA, USA). Sorbitol and sodium acetate were obtained from Aldrich. 0.9% Saline solution was purchased from Radix (Eau Claire, WI, USA). Distilled water (cell culture grade and endotoxin screened) was purchased from Gibco BRL.
Cell culture
Renca (mouse renal carcinoma) cells were a generous gift from Dr Drew Pardoll at the Johns Hopkins University. B16F10 (mouse melanoma, CRL 6322) and CV-1 (African Green monkey kidney, CCL 70) were obtained from American Type Tissue Culture Collection (ATCC, Rockville, MD, USA). Mark Cameron and Dr Gary Nabel kindly provided UM449 (human melanoma) and L293 cells (human embryonic kidney), respectively at the Uni-versity of Michigan. All cells were grown in Dulbecco's minimum essential medium containing 10% of fetal bovine serum and antibiotics. OptiMEM media (Gibco BRL) were used during the transfection procedure. Cells were maintained in a 5-7% CO 2 atmosphere at 37°C.
Plasmid DNA Plasmid DNA (VR1412) coding for ␤-galactosidase was constructed as described. 29 DNA was produced and purified according to Horn et al. 30 
Preparation of liposomes
The DMRIE:DOPE (1:1 molar ratio) lipid film was prepared as reported. 17 For the production of MLV, the dried lipid film was rehydrated by adding the appropriate vehicle (ie distilled water, 0.9% saline or 5% sorbitol/20 mm sodium acetate pH 6 buffer) in order to get a lipid concentration of 1-4 m. Then, vials were vortexed continuously for 2 min at the highest setting using a foam platform attached to a Genie-2 vortexer (Fisher), to produce the MLV. For the preparation of extruded cationic liposomes (large or small unilamellar vesicles, LUV or SUV), the MLV achieved in the previous step, were subjected to one freeze-thaw cycle before extrusion. The liposomes produced were passed through an 'extruder' (LipoFast; Avestin, Ottawa, Canada) mounted with a 100 or 400 nm polycarbonate track-etched membrane (PCTE filter) (Osmonics, Livermore, CA, USA) at room temperature. The liposomes were extruded 19 times back and forth according to the manufacturer's instruction. For the 400 nm extruded liposomes, the extrusion was performed with the aid of the ATI-Orion Sage syringe pump (Coast Scientific, La Jolla, CA, USA) at 100% flow rate and not manually (see below). Size determinations performed for other liposome formulations showed that liposomes formed by this technique are primarily unilamellar. 31 
Preparation of lipoplexes
Classical preparation of lipoplexes: One volume of MLV cationic liposomes prepared in various vehicles was mixed with one volume of DNA diluted in the same vehicle as the liposomes. Order of addition depends on the charge ratio used (see Results). DNA and cationic liposomes were mixed together at the desired DMRIE:DOPE/DNA molar ratio and used within 2 h after mixing. The nomenclature used for the lipoplex molar ratio corresponds to the number of mole of cationic lipids (DMRIE) per mole of DNA phosphate.
Controlled mixing method to prepare new lipoplex formulations: One volume of cationic liposomes and one volume of DNA are mixed together with the use of the ATIOrion sage syringe pump, in order to control the speed of mixing and eliminate the concern for the order of addition (Figure 3) . DNA solution and cationic liposomes were loaded into separate 1 ml tuberculin syringes which were then connected to an i.v. extension set equipped with a luer-lock adapter (6 inch) secured with a four-way stopcock/T-connector (Baxter, Chicago, IL, USA). Then, the DNA and liposomes were loaded independently (adjust the openings of the T-connector correspondingly) into the i.v. extension. With the port closed, the tuberculin syringe was exchanged with a 3, 5 or 10 ml syringe leaving a head space between the plunger and the solution. The syringe was placed on to the cradle of the pump, secured with the metal arm, and the plunger was adjusted on the syringes to put the fluid level at the same position for both DNA and liposome preparations. The mixing occurs when the carriage on the syringe pump pushes the plunger of the syringes simultaneously and at the same speed. The flow rate can be controlled either by using different size syringes and/or by adjusting the percentage flow dial on the syringe pump.
Analytical assays to characterize the lipoplex The percentage of DNA and lipid recovery, the determination of the lipoplex physical stability by filtration, the amount of free DNA in the formulations and the nuclease sensitivity assay were determined as described. 13 For the filtration assay, 600 l of lipoplex formulations or liposome control were filtered once (nonsequentially) through 0.4, 0.6 or 1 m PCTE membranes (Osmonics) using a 13-mm stainless steel filter housing (Fisher Scientific). The housing was cleaned after each sample by flushing 10 ml methanol followed by 10 ml MilliQ water through the filter housing and components and drying using filtered air. Total lipid and total DNA assays (fluorescamine and picogreen, respectively) were performed on filtered samples as described. 13 The DNA stability of the frozen lipoplexes was analyzed by agarose gel electrophoresis. After being store at −20°C for various times (from 1 week to 1 year), the DNA recovered from the lipoplex formulations was loaded on 0.8% agarose-0.1% SDS gel containing 0.5 g/ml of ethidium bromide to visualize the DNA using a trisacetate/EDTA buffer, pH 8. The lipid stability of the frozen lipoplexes was analyzed by thin layer chromatography (silica gel plate) with 75% chloroform-25% methanol as the mobile phase followed by extraction.
Particle size was determined by laser light scattering. All dynamic light scattering measurements were performed using a Malvern Zetasizer 4 (Malvern, PA, USA) equipped with a AZ104 cell at a scattering angle of 90°. The data were analyzed using the software supplied by the manufacturer in the Contin analysis mode. Samples were prepared by mixing the appropriate volume of the formulation or liposome control with 1.5 ml of the diluent and briefly vortexing in a 15-ml conical tube. For the lipoplexes produced by the classical method (Figure 1) , the lipid concentration ranged from 19 to 37.5 m and the DNA concentration varied from 1 to 50 g/ml (3 to 150 m) depending on the charge ratio used. The counting time for each sample was 180 s and the temperature was set at 25°C. The sample was diluted to give a 50-800 (×1000) counts per second. For instrument standardization, latex nanosphere size standards (Duke Scientific, Palo Alto, CA, USA) of 96, 200, 300 and 400 nm were tested. One hundred microliters of standard was mixed with 2.9 ml of water in a 15 ml conical tube, and further diluted 10-fold for measurement.
In vitro transfection assay Lipoplexes were prepared as described above at various molar ratios and in the three different vehicles. They were tested for their in vitro transfection efficiency in 96-well plates according to previously published protocols 17 with the exception that the serial dilution into 96-well plates of the DMRIE:DOPE/DNA complexes was done as follows: 75 l of the vehicle (water, 0.9% saline or 5% sorbitol/20 mm NaOAc pH 6) in which the formulation was prepared, was distributed into each well of an empty 96-well plate, then 75 l of the lipoplexes were transferred to the first well of each column 1 and 2× serial dilution was performed from column 1 to 12. Then, 75 l of OptiMEM was dispensed into each well and 100 l of this mixture was added to the cells. The sum of the pg ␤-galactosidase values obtained with the different formulations from the entire dilution series of the 96-well plate and expressed as the percentage of the pg sum value relative to the pg sum value obtained with the MLV prepared at 0.5 molar ratio and in the respective vehicle.
